EMAIL
In the rapidly advancing realm of respiratory medicine, relying solely on spirometry is insufficient for achieving precise lung function diagnoses. Compared with spirometry, the Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) test can obtain deeper insights into lung functions, leading to its widespread adoption by healthcare professionals. This advanced diagnostic method plays a pivotal role in the early and accurate detection of multiple lung conditions: it enables early identification of interstitial lung disease, facilitates monitoring of drug-induced pulmonary toxicity, and provides crucial information for differentiating between asthma and chronic obstructive pulmonary disease (COPD). Thus, DLCO test empowers healthcare professionals to make informed decisions, tailor treatment strategies, and ultimately improve patient outcomes across a spectrum of respiratory disorders.
Recognizing the significance of DLCO test, the American Thoracic Society (ATS) and European Respiratory Society (ERS) collaboratively published the 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung, building upon previous iterations, which represent a consensus between both societies regarding the technical requirements for DLCO instrumentation, with the ultimate goal of enhancing measurement accuracy. Notably, the 2017 ERS/ATS standards state unequivocally that "For every 100 ms increase in the 0–90% response time, the error in DLCO increases by about 0.7%," emphasizing the critical impact of response time as the linchpin of accuracy. Consequently, the ERS/ATS equipment specifications and performance standards mandate that the 0–90% response time in DLCO systems must not exceed 150 ms, setting a new benchmark for technological excellence in pulmonary function testing.
In response to the 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung, Cubic, a leading manufacturer of intelligent gas sensors and high-end scientific instruments, has risen to the challenge with the development of Gasboard-2051—an advanced DLCO gas sensor that not only meets the exacting 2017 ERS/ATS standards but also elevates the performance to new heights.
Leveraging Cubic mature platform of NDIR technology, Gasboard-2051 is developed to deliver CH4, CO and CO2 concentration measurements. Utilizing ultra-fast modulation frequency and a specialized detection circuit, Gasboard-2051 achieves a rapid response time of less than 150 milliseconds, thus ensuring real-time data accuracy. To further enhance the precise measurements of ultra-low concentrations of CH4 and CO gas during DLCO test, the device incorporates a sophisticated microcontroller for efficient gas sampling, signal processing, sensor calibration, and measurement output. To excel in the demanding environment of clinical settings, Gasboard-2051 is designed with built-in temperature and pressure compensation, maintaining high accuracy and exceptional stability across a wide range of atmospheric, temperature, and humidity conditions. As importantly, with its modular design, Gasboard-2051 ensures seamless integration with pulmonary function systems. By combining its superior accuracy and unwavering performance, Gasboard-2051 offers a turnkey solution for healthcare professionals seeking to elevate diagnostic capabilities in DLCO test.
As the healthcare industry continues to evolve, the demand for increasingly precise and sophisticated measurement tools is poised to grow exponentially. Cubic Gasboard-2051 is positioned at the forefront of this trend, offering healthcare professionals a reliable, high-performance solution that aligns with the most current international standards for DLCO test in pulmonology.
Looking ahead, Cubic remains steadfast in its commitment to advancing the development of innovative, intelligent, and diverse gas sensing solutions for the medical field, offering superior options to meet the burgeoning needs of the global healthcare market and contributing to the ongoing revolution in respiratory diagnostics.
